Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| PREH/2025-2-1 | Registry Identifier | Marcin Adam Zebalski |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Prehabilitation includes care for patients preparing for surgery. This is a modern approach aimed at increasing the patient's functional capacity before surgery and improving postoperative results. Prehabilitation includes preoperative physical activity, nutritional intervention, psychological support, cessation of stimulants and optimization of laboratory test results.
Many studies have shown a positive effect of prehabilitation on postoperative results, mainly reducing the number of postoperative complications and shortening the hospitalization time.
The assumed time of prehabilitation is 2-6 weeks, but in the case of oncology patients, the procedure should not be delayed only for the sake of prehabilitation.
Our study includes oncology patients with ovarian cancer who are referred for neoadjuvant chemotherapy before interval cytoreductive surgery. The assumption of the study is an intensive course of prehabilitation during neoadjuvant treatment, which should provide significantly better postoperative results.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intense course of prehabilitation | Experimental | Patients undergoing intense prehabilitation program |
|
| Standard preoperative care | No Intervention | Patients with standard preoperative care |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prehabilitation. An intensive prehabilitation for NACT patients | Procedure | Patients referred to NACT (neoadjuvant chemotheraphy) for advanced ovarian cancer will undergo an intensive course of prehabilitation including physical exercise, a high-protein diet, protein and vitamin supplementation, optimization of laboratory test results, and psychological support will be provided. |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of postoperative complications | Analysis of the incidence of complications, including assessment according to the Clavien-Dindo classification. Analysis of complications will include the incidence of intensive care units hospitalization, frequency of reoperation, dehiscence of intestinal anastomosis, wound dehiscence with eventeration, need for blood transfusion and readmission within 30 days | from surgery for the next 30 days |
| Length of hospital stay | The analysis will include the length of hospitalization after surgery. | from surgery to hospital discharge (assessed up to 14 days) |
| Time to start adjuvant chemotherapy | Comparison of time from hospital discharge to start of adjuvant chemotherapy | from discharge from hospital for the next 2 months |
| Measure | Description | Time Frame |
|---|---|---|
| Progression-free survival | Comparison of progression-free survival in both groups at 3 and 5 years of follow-up. | From the time of the operation for the next 3 and 5 years |
| Overall survival | Comparison of overall survival in both groups at 3 and 5 years of follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of life assessment | Measuring changes in quality of life during the prehabilitation program. The assessment of quality of life will be performed using the standardized EORTC Quality of Life QLQ-C30 questionnaire. The EORTC QLQ-C30 assesses quality of life in five functional domains (physical, role, cognitive, emotional, and social), three symptom domains (fatigue, pain, nausea and vomiting), a global health status domain (GHS/QoL), and five single-item domains (dyspnoea, insomnia, loss of appetite, constipation and diarrhea, and financial problems due to illness) The higher the score in the functional domains and in the global health status domain, the better the patient's quality of life, while the higher the score in the symptom domain, the worse the quality of life due to the severity of disease-related symptoms. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Krzysztof Nowosielski, MD, PhD | Department of Gynecology, Obstetrics and Gynecological Oncology, University Clinical Center of the Medical University of Silesia | Study Chair |
| Marcin A Zębalski, MD | Department of Gynecology, Obstetrics and Gynecological Oncology, University Clinical Center of the Medical University of Silesia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Gynecology, Obstetrics and Gynecological Oncology, University Clinical Center of the Medical University of Silesia | Katowice | 40-752 | Poland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010051 | Ovarian Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
Not provided
Not provided
The intervention group consists of patients undergoing prehabilitation
Not provided
Not provided
Not provided
Not provided
|
| From the time of the operation for the next 3 and 5 years |
| From study enrollment to surgery (up to 4 months) |
| Depression and anxiety assessment | Measuring changes in depression and anxiety during the prehabilitation program. The assessment of depression and anxiety will be performed using the HADS questionnaire. The HADS is a self-report questionnaire, and it consists of 2 subscales designed to identify and quantify anxiety and depression in patients, especially in oncological patients whereas a score of 8 points indicates mild anxiety or depression and the higher the score, the greater the severity of anxiety and depressive disorders. | from study enrollment to surgery (up to 4 months) |
| D000291 |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |